Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension

Journal of Cardiac Failure

Volumn 17, Issue 4, 2011, Pages 265-271

  Krasuski, Richard A ^a   Devendra, Ganesh P ^b   Hart, Stephen A ^b   Wang, Andrew ^a   Harrison, J Kevin ^a   Bashore, Thomas M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

mortality; pulmonary arterial hypertension; pulmonary hypertension; Vasodilator challenge

Indexed keywords

CREATININE; NITRIC OXIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; FEMALE; HEART RIGHT ATRIUM PRESSURE; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE BLIND PROCEDURE; SURVIVAL; TREATMENT RESPONSE; VASODILATATION;

ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; NITRIC OXIDE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79953208000     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.11.010     Document Type: Article

References (49)

1. R. Budhiraja, R.M. Tuder, and P.M. Hassoun Endothelial dysfunction in pulmonary hypertension Circulation 109 2004 159 165 (Pubitemid 38114133)
2. G. Cella, F. Bellotto, and F. Tona Plasma markers of endothelial dysfunction in pulmonary hypertension Chest 120 2001 1226 1230 (Pubitemid 32960098)
3. H.W. Farber, and J. Loscalzo Pulmonary arterial hypertension New Engl J Med 351 2004 1655 1665
4. S. Rich, D.R. Dantzker, and S.M. Ayres Primary pulmonary hypertension. A national prospective study Ann Intern Med 107 1987 216 223 (Pubitemid 17137857)
5. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group New Engl J Med 334 1996 296 302
6. V.V. McLaughlin, D.E. Genthner, M.M. Panella, and S. Rich Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension New Engl J Med 338 1998 273 277 (Pubitemid 28065252)
7. H. Olschewski, G. Simonneau, and N. Galie Inhaled iloprost for severe pulmonary hypertension New Engl J Med 347 2002 322 329 (Pubitemid 34815354)
8. V.V. McLaughlin, O. Sitbon, and D.B. Badesch Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Resp J 25 2005 244 249 (Pubitemid 40246523)
9. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension New Engl J Med 346 2002 896 903 (Pubitemid 34984638)
10. V.V. McLaughlin, S.P. Gaine, and R.J. Barst Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299 (Pubitemid 36135255)
11. R.N. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123 (Pubitemid 32971843)
12. C. Liu, and J. Cheng Endothelin receptor antagonists for pulmonary arterial hypertension Cochrane Database Systemic Ref 1 2005 CD004434
13. N. Skoro-Sajer, and I. Lang The role of treprostinil in the management of pulmonary hypertension Am J Cardiovasc Drugs 8 2008 213 217
14. B.K. Sastry, C. Narasimhan, N.K. Reddy, and B.S. Raju Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149 1153 (Pubitemid 38452588)
15. T.P. Singh, M. Rohit, A. Grover, S. Malhotra, and R. Vijayvergiya A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 2006 851.e851 851.e855
16. N. Benedict, A. Seybert, and M.A. Mathier Evidence-based pharmacologic management of pulmonary arterial hypertension Clin Therapeutics 29 2007 2134 2153 (Pubitemid 350138566)
17. N. Nagaya Drug therapy of primary pulmonary hypertension Am J Cardiovasc Drugs 4 2004 75 85 (Pubitemid 38578926)
18. C.W. Atwood Jr., D. McCrory, J.G. Garcia, S.H. Abman, and G.S. Ahearn American College of Chest Physicians. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines Chest 126 2004 72Se7S
19. D.B. Badesch, S.H. Abman, and G.S. Ahearn Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 2004 35S 62S (Pubitemid 38932341)
20. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension New Engl J Med 327 1992 76 81
21. G. Simonneau, N. Galie, and L.J. Rubin Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 2004 5S 12S (Pubitemid 38759712)
22. G. Simonneau, I.M. Robbins, and M. Beghetti Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 2009 S43 S54
23. M.C. Post, S. Janssens, F. Van de Werf, and W. Budts Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension Eur Heart J 25 2004 1651 1656 (Pubitemid 39209286)
24. S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties Chest 130 2006 841 846 (Pubitemid 44423618)
25. O. Sitbon, M. Humbert, and X. Jais Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension Circulation 111 2005 3105 3111 (Pubitemid 40847788)
26. H.H. Leuchte, M. Schwaiblmair, R.A. Baumgartner, C.F. Neurohr, T. Kolbe, and J. Behr Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension Chest 125 2004 580 586 (Pubitemid 38223639)
27. J. Morales-Blanhir, S. Santos, and L. de Jover Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension Respir Med 98 2004 225 234 (Pubitemid 38262656)
28. O. Raffy, R. Azarian, and F. Brenot Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension Circulation 93 1996 484 488
29. M.J. Ricciardi, B.P. Knight, F.J. Martinez, and M. Rubenfire Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine J Am Coll Cardiol 32 1998 1068 1073 (Pubitemid 28459601)
30. D.H. Roberts, J.J. Lepore, A. Maroo, M.J. Semigran, and L.C. Ginns Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension Chest 120 2001 1547 1555 (Pubitemid 33078471)
31. O. Sitbon, F. Brenot, and A. Denjean Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin Am J Resp Crit Care Med 151 1995 384 389
32. O. Sitbon, M. Humbert, and J.L. Jagot Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension The Eur Resp J 12 1998 265 270 (Pubitemid 28389516)
33. H.A. Ghofrani, M.W. Wilkins, and S. Rich Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension Circulation 118 2008 1195 1201
34. N. Skoro-Sajer, N. Hack, and R. Sadushi-Kolici Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study Circulation 119 2009 298 305
35. S.L. Archer, and E.D. Michelakis An evidence-based approach to the management of pulmonary arterial hypertension Curr Opin Cardiol 21 2006 385 392 (Pubitemid 44315072)
36. R.J. Barst, M. McGoon, and A. Torbicki Diagnosis and differential assessment of pulmonary arterial hypertension J Am Coll Cardiol 43 2004 40S 47S (Pubitemid 38759716)
37. R.A. Krasuski, J.J. Warner, A. Wang, J.K. Harrison, V.F. Tapson, and T.M. Bashore Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J Am Coll Cardiol 36 2000 2204 2211
38. J. Pepke-Zaba, T.W. Higenbottam, A.T. Dinh-Xuan, D. Stone, and J. Wallwork Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension Lancet 338 1991 1173 1174
39. D.L. Wessel, I. Adatia, J.E. Thompson, and P.R. Hickey Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension Crit Care Medi 22 1994 930 938 (Pubitemid 24182722)
40. R.J. Oudiz, N. Galie, and H. Olschewski Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981
41. Y.F. Chen, S. Jowett, and P. Barton Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation Health Technol Assess 13 2009 1 320
42. N. Galie, L. Rubin, and M. Hoeper Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2008 2093 2100 (Pubitemid 351902178)
43. D. Montani, M.C. Chaumais, and L. Savale Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension Adv Ther 26 2009 813 825
44. S.L. Archer, and E.D. Michelakis Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension N Engl J Med 361 2009 1864 1871
45. Z.C. Jing, X. Jiang, and B.X. Wu Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study Heart 95 2009 1531 1536
46. R.J. Barst, J.S. Gibbs, and H.A. Ghofrani Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S78 S84
47. G. Simonneau, L.J. Rubin, and N. Galie Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
48. D.B. Taichman Therapy for pulmonary arterial hypertension: the more, the merrier? Ann Intern Med 149 2008 583 585
49. N. Galie, A. Manes, L. Negro, M. Palazzini, M.L. Bacchi-Reggiani, and A. Branzi A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403